araag2/HINT huggingface dataset:
Clinical trial NCT01197261 (phase 2, status: completed)
Conditions: interstitial cystitis, painful bladder syndrome, pain
ICD codes: N30.10, N30.11, D68.61, D69.41, D81.4, E24.1, E26.01, E26.81, E34.0, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: oxycodone naloxone prolonged release tablets, placebo tablets
SMILES: CC(=O)OC1=CC=CC=C1C(O)=O, NC[C@H]1CC[C@@H](CC1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  History of severe pain due to Bladder Pain Syndrome (BPS) for at least 6 months

          -  Subject's treatment of pain due to BPS is insufficient

          -  Subjects must not have received opioid containing medication in the last 6 months

        Exclusion Criteria:

          -  Females who are pregnant or lactating

          -  Subjects with any contraindication/history of hypersensitivity to oxycodone, naloxone,
             paracetamol, related products or other ingredients

          -  Subjects with any situation in which opioids are contraindicated like severe
             respiratory depression with hypoxia and/or hypercapnia, severe chronic obstructive
             lung disease, cor pulmonale, severe bronchial asthma or paralytic ileus

          -  Evidence of clinically significant cardiovascular, renal, hepatic, gastrointestinal or
             psychiatric disease, as determined by medical history, clinical laboratory tests, ECG
             results, and physical examination that would place the subject at risk upon exposure
             to the study medication or that may confound the analysis and/or interpretation of the
             study results

          -  Abnormal aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatise
             levels (> 3 times the upper limit of normal), gamma glutamyl transpeptidase > 3 times
             the upper limit of normal

          -  Abnormal total bilirubin and/or creatinine level(s)
Clinical trial NCT00111800 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo, den 2.5 mg, den 7.5 mg, den 15 mg, den 30 mg, den 45 mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Women must not be pregnant and must not be breastfeeding.

          -  Have Type II diabetes.

          -  Not taking any medicine for diabetes, or taking one oral medicine for their diabetes.

        Exclusion criteria:

          -  Have any underlying or significant active disease that would prevent the subject from
             safely participating in the trial by the judgement of the study doctor.
Clinical trial NCT00595101 (phase 2, status: completed)
Conditions: primary open angle glaucoma, ocular hypertension
ICD codes: H40.1130, H40.1131, H40.1132, H40.1133, H40.1134, H40.1110, H40.1111, H40.053, H40.051, H40.052, H40.059
Drugs: pf-03187207, latanoprost 0.005%, pf-03187207 vehicle, latanoprost vehicle
SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1, CC1=CC(O)=CC(C)=C1Cl, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Man or woman at least 20 years of age

          -  Diagnosis of primary open-angle glaucoma or ocular hypertension in one or both eyes.

        Exclusion Criteria:

          -  Closed/barely open anterior chamber angle or a history of acute angle closure in
             either eye

          -  Contraindications to latanoprost and nitric oxide treatment

          -  Known latanoprost non-responders
Clinical trial NCT00672659 (phase 2, status: completed)
Conditions: depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: citalopram + pipamperone, citalopram
SMILES: NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients

          -  18-65 years inclusive

          -  Suffering from a moderate to severe MDD as defined by DSM IV with an existence of
             depressed mood and loss of interest/anhedonia for at least four weeks and no longer
             than six months for the current episode

          -  Diagnosis will be confirmed by the Mini International Neuropsychiatric Interview
             (MINI) version 5.0.0.

          -  Clinical global impression - severity scale (CGI-S) rating of at least four and a
             minimum Hamilton Depression Scale (HAM-D) 17 items total score of 18 at screen and
             baseline

          -  A non-psychotic state

          -  Where appropriate, male patients should agree to use barrier contraceptive measures
             (condoms) during the course of the study and for three months after the last dose of
             medication

        Exclusion Criteria:

          -  Premenopausal females not using adequate contraceptive measures

          -  Considered by the investigator to be a significant risk of suicide or scoring 5 or
             more on the MADRS question 10

          -  Significant other psychiatric illness which would interfere with trial assessments -
             co-morbid generalised anxiety disorder (GAD) and panic disorder will be permitted
             where MDD is considered the primary diagnosis

          -  Significant physical illness which would interfere with trial assessments

          -  Reduced hepatic function

          -  Epilepsy

          -  History of cardiac dysrhythmia

          -  Alcohol intake above accepted UK ranges

          -  Recent (1 week) antidepressant (except for fluoxetine - 4 weeks and St John's Wort or
             MAOI's - 14 days), benzodiazepine or any other psychotropic medication ingestion
             including lithium or other mood stabilisers

          -  Resistant depression defined as having failed to respond to

               -  Two previous antidepressants at an adequate dose ingested for at least 4 weeks
                  during the current episode

               -  To an augmentation therapy with an atypical antipsychotic drug

          -  Electroconvulsive therapy (ECT) for the current episode

          -  Formal psychotherapy or alternative treatments for one week prior to or during the
             study
Clinical trial NCT00420784 (phase 2, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: telaprevir, ribavirin, pegylated interferon alfa 2a, matching placebo
SMILES: [H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females between 18 and 70 years old

          -  Detectable plasma hepatitis C virus (HCV) ribonucleic acid (RNA) greater than or equal
             to (>=) 10,000 international units per milliliter (IU/mL)

          -  Must have chronic hepatitis C (genotype 1) and have already received at least one
             prior course of pegylated interferon alfa 2a with ribavirin

          -  Cannot also be infected with Human Immunodeficiency Virus or hepatitis B

          -  Must be judged to be in general good health and able to receive Pegasys® and Copegus®

          -  No drug or alcohol abuse in the last year

          -  Must agree to use two effective methods of birth control during the study and for 6
             months after you stop taking study medication. One of the methods needs to be a
             'barrier' method (condom or diaphragm)

          -  If you are a woman, you cannot be in this study if you are pregnant or nursing

        Exclusion Criteria:

          -  Participation in any clinical trial of a HCV protease inhibitor of any duration

          -  Prior response to therapy and failure to achieve SVR which was due to treatment
             non-compliance

          -  Any other cause of significant liver disease in addition to hepatitis C; this may
             include but is not limited to, hepatitis B, drug or alcohol-related cirrhosis,
             autoimmune hepatitis, hemochromatosis, Wilson's disease, nonalcoholic steatohepatitis,
             or primary biliary cirrhosis

          -  Diagnosed or suspected hepatocellular carcinoma

          -  History of or current evidence of decompensated liver disease

          -  Participation in any clinical trial of an investigational drug within 90 days before
             drug administration or participation in more than 2 drug studies in the last 12 months
             (exclusive of the current study)
Clinical trial NCT01125189 (phase 2, status: completed)
Conditions: hepatitis c virus
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: daclatasvir, daclatasvir, placebo, peg-interferon alfa-2a, ribavirin
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients chronically infected with hepatitis C virus (HCV) genotype 1 or 4

          -  HCV RNA viral load of ≥100,000 IU/mL

          -  No previous exposure to interferon, pegIFNα, or RBV

          -  Results of a liver biopsy demonstrating absence of cirrhosis obtained ≤24 months prior
             to randomization. Compensated cirrhotics with Hepatitis C virus genotype 1 infection
             are eligible, but will be capped at 10% of the randomized study population (biopsy can
             be from any time period prior to randomization)

          -  Findings on ultrasound, computed tomography scan, or magnetic resonance imaging 12
             months prior to randomization that do not demonstrate evidence of hepatocellular
             carcinoma

          -  Body mass index of 18 to 35 kg/m^2

        Exclusion Criteria:

          -  Positive for hepatitis B or HIV-1/HIV-2 antibody at screening

          -  Evidence of a medical condition associated with chronic liver disease other than HCV

          -  Evidence of decompensated cirrhosis based on radiologic criteria or biopsy
Clinical trial NCT00485472 (phase 2, status: terminated)
Conditions: osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: lacosamide
SMILES: COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
Reason stopped: 
    based on the outcome of the planned first interim analysis, it was decided not to continue the
    trial. no safety concerns were identified.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subject has symptomatic osteoarthritis of the knee diagnosed using clinical and
             radiographic evidence as well as ACR criteria with symptom duration of at least 6
             months.

          -  Subject requires therapeutic dose of an NSAID, COX-2 NSAID, and/or
             paracetamol/acetaminophen for osteoarthritis pain of the index knee and has taken that
             medication at least 5 days per week for the last 4 weeks prior to the screening visit
             (Visit 1).

        Exclusion Criteria:

          -  Subject is not able to withdraw NSAIDs, COX-2 NSAIDs and/or paracetamol

          -  Subject is taking analgesic other than NSAIDs COX-2 NSAIDs and/or paracetamol

          -  Subject is planning to begin or stop treatment with glucosamine and/or chondroitin
             during the trial
Clinical trial NCT00054119 (phase 2, status: completed)
Conditions: primary peritoneal carcinoma, recurrent ovarian carcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: cositecan
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C(CC[Si](C)(C)C)C4=CC=CC=C4N=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed ovarian epithelial or primary peritoneal cancer

               -  Recurrent or persistent disease

               -  Platinum-resistant disease

          -  At least 1 unidimensionally measurable lesion

               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan

          -  At least 1 target lesion to assess response (tumors within a previously irradiated
             field are designated as non-target)

          -  Ineligible for a higher priority GOG study or other phase II cytotoxic study for
             platinum-resistant disease

          -  Performance status - GOG 0-2

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  ALT no greater than 2.5 times ULN

          -  Alkaline phosphatase no greater than 2.5 times ULN

          -  Creatinine no greater than 1.5 times ULN

          -  No myocardial infarction within the past 6 months

          -  No cerebrovascular accident within the past 6 months

          -  No transient ischemic attack within the past 6 months

          -  No uncontrolled hypertension

          -  No decompensated or uncontrolled chronic heart failure

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No neuropathy (sensory or motor) grade 2 or greater

          -  No other invasive malignancies within the past 5 years except nonmelanoma skin cancer

          -  No active infection requiring antibiotics

          -  At least 3 weeks since prior biological or immunological agents

          -  See Disease Characteristics

          -  At least 3 weeks since prior chemotherapy and recovered

          -  No more than 2 prior cytotoxic chemotherapy regimens, with no more than 1
             non-platinum, non-taxane regimen

          -  No prior karenitecin or camptothecin analogue/derivative

          -  At least 1 week since prior hormonal therapy

               -  Concurrent hormone replacement therapy allowed

          -  See Disease Characteristics

          -  At least 3 weeks since prior radiotherapy and recovered

          -  No prior radiotherapy to more than 25% of marrow-bearing areas

          -  Recovered from recent surgery

          -  At least 3 weeks since prior therapy directed at this malignancy

          -  No prior anticancer therapy that would preclude study therapy

          -  No concurrent amifostine or other protective reagents
Clinical trial NCT00538681 (phase 2, status: terminated)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: enzastaurin, pemetrexed, cisplatin, placebo
SMILES: CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    terminated due to lack of efficacy demonstrated in relevant participant population in other
    clinical trials.
  
Eligibility criteria:

        Inclusion Criteria:

          -  diagnosis of advanced NSCLC not amenable to curative treatment. Participants enrolling
             in Part 2 of the study must have the above stated diagnosis of NSCLC that is also of
             nonsquamous histology.

          -  no prior systemic therapies [chemotherapy, et cetera (etc.)] or pleurodesis with
             chemotherapy for this disease

          -  prior radiotherapy is allowed but must be completed at least 2 weeks before study
             enrollment and participant must be recovered from the acute toxic effects

          -  have a good performance status

          -  participant must sign an informed consent document

        Exclusion Criteria:

          -  participant had myocardial infarction occurring less than 6 months before inclusion,
             uncontrolled arrhythmia, symptomatic angina pectoris, or cardiac failure not
             controlled by medications

          -  participant is unable to swallow tablets

          -  participant is taking a certain medicine to control seizure activity, called "enzyme
             inducing antiepileptic drugs" and is not able to stop taking the medicine prior to
             enrolling in the study

          -  participant is unable to interrupt aspirin and/or other anti-inflammatory agents

          -  participant is unwilling or unable to take vitamin supplementation (folic acid and
             vitamin B12) or medications to prevent side effects
Clinical trial NCT00518583 (phase 2, status: unknown status)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: pegylated liposomal doxorubicin (doxil)
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Dx of clinical T1c-T3, N0-1, M0 breast cancer

          -  Interval between diagnosis and consent of <- 62 days

          -  Life expectancy of 10 years

          -  LVEF by MUGA >= lower limit of normal for the testing facility

          -  Negative serum pregnancy test

          -  Adequate bone marrow, renal, liver function

          -  Negative bone scan

          -  HRT discontinued before study entry

          -  Adequate contraceptive methods

        Exclusion Criteria:

          -  Male breast cancer

          -  Less than 21 years of age

          -  Ulceration, infiltration of the skin, complete fixation or severe skin edema

          -  N3 disease in which nodes are matted and fixed

          -  Suspicious palpable supraclavicular nodes

          -  CT evidence of malignant internal mammary nodes

          -  Pregnancy or breast feeding at time of study entry

          -  Prior therapy for breast cancer

          -  Prior anthracycline for any malignancy

          -  Prior breast malignancy of the contralateral breast

          -  Prior non-breast malignancy within 5 years

          -  Non-malignant disease that would preclude follow up

          -  MI within 6 months, NYHA Class II or greater heart failure

          -  Psychiatric disorders or conditions that would preclude provision of informed consent
Clinical trial NCT00530530 (phase 2, status: completed)
Conditions: restless legs syndrome
ICD codes: G25.81
Drugs: asp8825, placebo
SMILES: CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with RLS, based on the International RSL Study Group Diagnostic Criteria

          -  History of RLS symptoms at least 15 nights in the prior month or, if on treatment,
             this frequency of symptoms before treatment was started

          -  Documented RLS symptoms for at least 4 of the 7 consecutive evenings/ nights during
             the baseline study period

        Exclusion Criteria:

          -  A sleep disorder (e.g., sleep apnea) that may significantly affect the assessment of
             RLS

          -  A history of RLS symptom augmentation or end-of-dose rebound with previous dopamine
             agonist treatment

          -  Neurologic disease or movement disorder (e.g., diabetic neuropathy, Parkinson's
             Disease, Multiple Sclerosis, dyskinesias and dystonias
Clinical trial NCT00391729 (phase 2, status: completed)
Conditions: attention-deficit/hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: abt-089, placebo
SMILES: CC1=C(OC[C@@H]2CCCN2)C=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Meet criteria for attention deficit hyperactivity disorder

          -  Have voluntarily signed an informed consent form

          -  Are between 18 and 60 years of age

          -  Will use contraceptive methods during the study

          -  Women must not be pregnant or breast-feeding

          -  Must be in generally good health

          -  Are fluent in English

        Exclusion Criteria:

          -  They have a current or past diagnosis of schizoaffective disorder, schizophrenia,
             obsessive-compulsive disorder, drug-induced psychosis, bipolar disorder, psychotic
             disorder or mental retardation

          -  They have a current diagnosis of major depressive episode, generalized anxiety
             disorder (GAD), or post-traumatic stress disorder (PTSD) or have a clinically
             significant sleep disorder requiring treatment

          -  They require ongoing treatment or expected treatment with any psychotropic medication,
             including anxiolytics, antipsychotics, anticonvulsants, antidepressants or mood
             stabilizers

          -  They failed to respond to two or more adequate trials of FDA-approved ADHD medication

          -  They have violent, homicidal or suicidal ideation

          -  They have a significant history of medical diagnoses, seizure disorder, Tourette's
             syndrome or a central nervous system (CNS) disease, excluding ADHD

          -  They have a urine drug screen that is positive for alcohol or drugs of abuse

          -  They have a history of substance or alcohol disorder (abuse/dependence) during the
             last 3 months
Clinical trial NCT00551213 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: irinotecan, capecitabine, folfox, capeox/xelox, folfiri
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, FC1=CNC(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Older than 18 years of age, of any race, and gender;

          -  Diagnosis of histologically confirmed relapsed or recurrent colorectal carcinoma that
             has progressed on at least first-line therapy;

          -  Must have a computed tomography (CT) or magnetic resonance imaging (MRI) scan
             performed at some point during their immediate prior treatment or observation in order
             to determine tumor growth rate;

          -  Must have measurable disease on a CT or MRI study, performed during Screening;

          -  Must have an Eastern Cooperative Oncology Group (ECOG) performance status of <=2 and a
             minimum life expectancy of ≥4 months;

          -  Must have adequate organ function within 3 weeks prior to treatment assignment

        Exclusion Criteria:

          -  History of another malignancy;

          -  Known treated or untreated leptomeningeal metastasis, or a metastatic central nervous
             system lesion;

          -  Surgery within 3 weeks;

          -  Radiation therapy within 6 weeks;

          -  A history of uncontrolled diabetes mellitus, defined as a hemoglobin A1C of >7.5% in a
             participant with known diabetes mellitus;

          -  A recent myocardial infarction (within the past year); or a participant who at the
             time of Screening presents with unstable or uncontrolled angina, New York Heart
             Association Class III or IV congestive heart failure, uncontrolled hypertension,
             clinically significant cardiac dysrhythmia or clinically significant electrocardiogram
             abnormality;

          -  An active infection;

          -  Has clinically significant hepatitis at Screening, or is hepatitis C antibody
             positive, hepatitis B surface antigen positive, or human immunodeficiency virus (HIV)
             seropositive.